These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
552 related articles for article (PubMed ID: 26450434)
1. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?]. Schreiber S Z Rheumatol; 2015 Oct; 74(8):689-94. PubMed ID: 26450434 [TBL] [Abstract][Full Text] [Related]
4. An update on biosimilar drugs for inflammatory bowel disease. Schreiber S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529 [TBL] [Abstract][Full Text] [Related]
5. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Pouillon L; Bossuyt P; Peyrin-Biroulet L Expert Opin Biol Ther; 2016 Oct; 16(10):1277-90. PubMed ID: 27329436 [TBL] [Abstract][Full Text] [Related]
6. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A; Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290 [TBL] [Abstract][Full Text] [Related]
8. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases. Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107 [TBL] [Abstract][Full Text] [Related]
9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
10. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar. Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022 [TBL] [Abstract][Full Text] [Related]
11. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
12. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD). Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F; Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575 [No Abstract] [Full Text] [Related]
13. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology]. Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. Peyrin-Biroulet L; Danese S; Cummings F; Atreya R; Greveson K; Pieper B; Kang T Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):731-738. PubMed ID: 31322440 [No Abstract] [Full Text] [Related]
15. [Biosimilars]. Burmester GR; Müller-Ladner U Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433 [No Abstract] [Full Text] [Related]
16. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532 [TBL] [Abstract][Full Text] [Related]
17. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Reinisch W; Louis E; Danese S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531 [TBL] [Abstract][Full Text] [Related]
19. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. Zheng MK; Shih DQ; Chen GC World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. Martelli L; Peyrin-Biroulet L Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]